Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma
暂无分享,去创建一个
J. Sham | D. Kwong | D. Chua | M. Ng | B. Zheng | D. Kwong | Liwei Lu | D. Chua | K. Cao | Ying Zheng | S. Ng
[1] T. H. Bø,et al. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles , 2005, Cytometry. Part B, Clinical cytometry.
[2] R. Foà,et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. , 2005, Haematologica.
[3] H. Ikeda,et al. The critical role of type‐1 innate and acquired immunity in tumor immunotherapy , 2004, Cancer science.
[4] L. Malmgaard. Induction and regulation of IFNs during viral infections. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[5] I. McInnes,et al. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. , 2004, Current opinion in pharmacology.
[6] O. Hrusak,et al. Antigen expression patterns reflecting genotype of acute leukemias , 2002, Leukemia.
[7] J. Sham,et al. Peripheral γδ T‐cell deficit in nasopharyngeal carcinoma , 2002 .
[8] F. Shi,et al. The Natural Killer Cell – Friend or Foe in Autoimmune Disease? , 2002, Scandinavian journal of immunology.
[9] I. McInnes,et al. The role of innate mediators in inflammatory response. , 2002, Molecular immunology.
[10] M. Collins,et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. , 2002, Immunity.
[11] N. Day,et al. Innate immunity and its role against infections. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] Eric O Long. Tumor cell recognition by natural killer cells. , 2002, Seminars in cancer biology.
[13] A. Luster. The role of chemokines in linking innate and adaptive immunity. , 2002, Current opinion in immunology.
[14] C. Biron,et al. Innate immune responses to LCMV infections: natural killer cells and cytokines. , 2002, Current topics in microbiology and immunology.
[15] D. Pardoll. Stress, NK Receptors, and Immune Surveillance , 2001, Science.
[16] K. Yuen,et al. Adoptive transfer of autologous Epstein‐Barr virus–specific cytotoxic T cells for nasopharyngeal carcinoma , 2001, International journal of cancer.
[17] Julia M. Lewis,et al. Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.
[18] C. Feighery,et al. Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-151 , 2001, The Journal of Immunology.
[19] A. Diefenbach,et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.
[20] Ciriana Orabona,et al. Positive Regulatory Role of IL-12 in Macrophages and Modulation by IFN-γ1 , 2001, The Journal of Immunology.
[21] Brubaker Jo,et al. Role of interleukin-13 in innate and adaptive immunity. , 2001 .
[22] H. Tilg,et al. Interferon-alpha in inflammation and immunity. , 2001, Cellular and molecular biology.
[23] Jonathan W. Heusel,et al. Vital Involvement of a Natural Killer Cell Activation Receptor in Resistance to Viral Infection , 2001, Science.
[24] K. Chan,et al. Anti‐tumor effects of human peripheral γδ T cells in a mouse tumor model , 2001 .
[25] Pei-Hua Lu,et al. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells , 2001, Cancer Immunology, Immunotherapy.
[26] C. Wong,et al. Distinct Tumour Specificity and IL‐7 Requirements of CD56−and CD56+ Subsets of Human γδ T Cells , 2001 .
[27] T. Kishida,et al. Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer , 2001, Cancer Immunology, Immunotherapy.
[28] L. Lanier,et al. Immune inhibitory receptors. , 2000, Science.
[29] O. Tsitsilonis,et al. Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice , 2000, European journal of immunology.
[30] Y. Kanda,et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia , 2000, Cancer.
[31] D. Kabelitz,et al. Antigen Recognition by Human γδ T Lymphocytes , 2000, International Archives of Allergy and Immunology.
[32] A. Ramsay,et al. Cytokines in innate and adaptive immunity. , 2000, Reviews in immunogenetics.
[33] C. Biron,et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.
[34] K. Hellström,et al. T cell immunity to tumor antigens. , 1998, Critical reviews in immunology.
[35] P Parham,et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. , 1997, Immunity.
[36] L. Axelsson,et al. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. , 1997, Blood.
[37] E. Podack,et al. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. , 1996, Journal of immunology.
[38] M. Ferrarini,et al. Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes. , 1995, Journal of immunology.
[39] R. Martin,et al. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. , 1994, Journal of immunological methods.
[40] M. Jourdan,et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.
[41] X M Wang,et al. A new microcellular cytotoxicity test based on calcein AM release. , 1993, Human immunology.
[42] A. Komiyama,et al. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection. , 1987, Clinical and experimental immunology.
[43] J. Ho. Stage classification of nasopharyngeal carcinoma: a review. , 1978, IARC scientific publications.